BR112014007042A8 - Métodos e composições para reduzir níveis séricos de triacilglicerídeos em seres humanos que utilizam uma lipase fúngica - Google Patents

Métodos e composições para reduzir níveis séricos de triacilglicerídeos em seres humanos que utilizam uma lipase fúngica

Info

Publication number
BR112014007042A8
BR112014007042A8 BR112014007042A BR112014007042A BR112014007042A8 BR 112014007042 A8 BR112014007042 A8 BR 112014007042A8 BR 112014007042 A BR112014007042 A BR 112014007042A BR 112014007042 A BR112014007042 A BR 112014007042A BR 112014007042 A8 BR112014007042 A8 BR 112014007042A8
Authority
BR
Brazil
Prior art keywords
compositions
methods
triacylglycerides
human subjects
reducing serum
Prior art date
Application number
BR112014007042A
Other languages
English (en)
Other versions
BR112014007042A2 (pt
Inventor
Gregory Moore Kenneth
Schuler Christopher
Schuler Edward
S Penet Christopher
Gregory Kelly
Original Assignee
Gregory Moore Kenneth
Bio Cat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gregory Moore Kenneth, Bio Cat Inc filed Critical Gregory Moore Kenneth
Publication of BR112014007042A2 publication Critical patent/BR112014007042A2/pt
Publication of BR112014007042A8 publication Critical patent/BR112014007042A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS E COMPOSIÇÕES PARA REDUZIR NÍVEIS SÉRICOS DE TRIACILGLICERÍDEOS EM SERES HUMANOS QUE UTILIZAM UMA LIPASE FÚNGICA. A presente invenção refere-se a métodos e composições para reduzir os níveis séricos de triacilglicerídeos em seres humanos. Em particular, a invenção refere-se à administração oral de uma quantidade eficaz de uma formulação de lipase fúngica, para um ser humano com níveis séricos elevados ou limítrofes elevados de triacilglicerídeos, por um período de tempo suficiente para reduzir os níveis de triacilglicerídeo séricos.
BR112014007042A 2011-09-23 2012-09-18 Métodos e composições para reduzir níveis séricos de triacilglicerídeos em seres humanos que utilizam uma lipase fúngica BR112014007042A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/244,131 US8268305B1 (en) 2011-09-23 2011-09-23 Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
PCT/US2012/055899 WO2013043587A1 (en) 2011-09-23 2012-09-18 Methods and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase

Publications (2)

Publication Number Publication Date
BR112014007042A2 BR112014007042A2 (pt) 2017-04-11
BR112014007042A8 true BR112014007042A8 (pt) 2018-04-03

Family

ID=46800675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007042A BR112014007042A8 (pt) 2011-09-23 2012-09-18 Métodos e composições para reduzir níveis séricos de triacilglicerídeos em seres humanos que utilizam uma lipase fúngica

Country Status (8)

Country Link
US (2) US8268305B1 (pt)
EP (1) EP2758070B1 (pt)
JP (1) JP6170051B2 (pt)
AU (1) AU2012312661B2 (pt)
BR (1) BR112014007042A8 (pt)
CA (1) CA2849250C (pt)
MX (1) MX368742B (pt)
WO (1) WO2013043587A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US496A (en) 1837-12-01 Mode of com-stbuctiire sawmills fob sawing timber
US6699A (en) 1849-09-04 Improvement in street-sweeping machines
GB1084431A (en) 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE1964909A1 (de) 1969-12-24 1971-07-08 Jungheinrich & Co Maschf Kehrsaugmaschine und Kehrwalze fuer eine Kehrsaugmaschine
GB1503653A (en) 1974-03-07 1978-03-15 Unilever Ltd Yeast containing food emulsions
US3898130A (en) 1974-03-18 1975-08-05 American Hospital Supply Corp Rapid enzymatic hydrolysis of triglycerides
US4056442A (en) 1976-06-01 1977-11-01 The Dow Chemical Company Lipase composition for glycerol ester determination
FR2362863A1 (fr) 1976-08-24 1978-03-24 Degussa Preparations de lipases a action amelioree et preparations medicales ameliorees contenant des lipases d'origine non animale
US4245041A (en) 1977-12-07 1981-01-13 American Monitor Corporation Triglycerides assay and reagents therefor
US4264589A (en) 1978-12-20 1981-04-28 Felts James M Separation of active α1 -acid glycoprotein and utilization in the lipoprotein lipase enzyme system
JPS5584397A (en) 1978-12-20 1980-06-25 Ajinomoto Kk Fat and oil ester exchange using lipase
US4394445A (en) 1979-02-22 1983-07-19 Nix Paul T Enzymatic glyceride hydrolysis
US4259440A (en) 1979-05-21 1981-03-31 Miles Laboratories, Inc. Hydrolysis and assay of triglycerides
US4251519A (en) 1979-07-30 1981-02-17 Anheuser-Busch, Incorporated Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels
DK0387945T3 (da) 1989-03-08 1993-12-20 Simon Lodewijk Scharpe Middel til behandling af eksokrin pancresinsufficiens og midlets anvendelse til fremstilling af et lægemiddel til behandlingen
US5108916A (en) 1989-06-05 1992-04-28 Rhone-Poulenc Rorer, S.A. Process for stereoselectively hydrolyzing, transesterifying or esterifying with immobilized isozyme of lipase from candida rugosa
DK95490D0 (da) 1990-04-18 1990-04-18 Novo Nordisk As Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5262172A (en) 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5234697A (en) 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
RU2040932C1 (ru) 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
WO1996038170A1 (en) 1995-05-31 1996-12-05 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
DE19649097A1 (de) 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Lipasen
KR100516561B1 (ko) 1996-12-06 2005-09-22 아벤티스 파마슈티칼스 인크. 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법
EP1067945B1 (en) 1998-04-01 2006-01-04 Ganeden Biotech, Inc. Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
JP2000226335A (ja) * 1998-12-04 2000-08-15 Amano Pharmaceut Co Ltd 経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法
NZ514826A (en) 1999-03-17 2003-08-29 Solvay Pharm Gmbh Medicinal product for the treatment of diabetes
DE60040548D1 (de) 1999-07-21 2008-11-27 Yakult Honsha Kk Mittel zur senkung von cholesterin, mittel zur hemmung der produktion von sekundären gallensäuren, nahrungsmittel und getränke
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2003016518A1 (en) 2001-08-13 2003-02-27 Bayer Healthcare Ag Regulation of human triacylglycerol lipase
ATE492166T1 (de) 2002-04-05 2011-01-15 Nestle Sa Zusammensetzungen und verfahren zur verbesserung von lipidassimilation in haustieren
US6660508B1 (en) 2002-06-28 2003-12-09 Ultra Biotech Limited Dietary supplements for treating hyperlipemia
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
US7067124B2 (en) 2003-03-28 2006-06-27 National Enzyme Company Protease composition and method for treating a digestive disorder
US7223401B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
AU2005227090B2 (en) 2004-03-22 2010-12-09 Abbott Laboratories Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
DE602005022187D1 (de) 2004-05-24 2010-08-19 Novozymes As Enzyme für pharmazeutische anwendung
PT2198880T (pt) 2004-10-14 2017-01-04 Lilly Co Eli Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
US20060084153A1 (en) 2004-10-15 2006-04-20 Wuli Bao Method of producing diacylglycerides
EP1910530A2 (en) 2005-05-31 2008-04-16 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
NZ563777A (en) 2005-06-24 2010-08-27 Novozymes As Serine protease derived from Bacillus licheniformis optionally in combination with lipases and amylases for pharmaceutical use
US8017351B2 (en) 2005-06-24 2011-09-13 Novozymes A/S Amylases for pharmaceutical use
KR20080017025A (ko) 2005-06-24 2008-02-25 노보자임스 에이/에스 약학적 용도의 리파제
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
EP2216403A3 (en) 2006-02-02 2010-11-24 Verenium Corporation Esterases and related nucleic acids and methods
EP2061483A1 (en) 2006-09-07 2009-05-27 McGill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
MX2009006597A (es) 2006-12-21 2009-07-02 Novozymes As Variantes de lipasa para uso farmaceutico.
US20080199448A1 (en) 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
AU2008239737A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
FR2927254B1 (fr) 2008-02-12 2010-03-26 Lesaffre & Cie Utilisation de substances actives naturelles dans des compositions cosmetiques ou therapeutiques
US20090317371A1 (en) 2008-06-08 2009-12-24 Saccharides Science & Technology Ltd. Method, Composition, and Device, for the Treatment of Amylase Malfunctions / Inactivity in Association with Saccharides (Mainly Polysaccharides) Based Diseases
WO2010020693A2 (en) 2008-08-21 2010-02-25 Novozymes A/S Enzymes for the treatment of obesity
WO2010025126A1 (en) 2008-08-26 2010-03-04 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
EP2328566A1 (en) 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
EP2786761A1 (de) 2009-01-29 2014-10-08 Nordmark Arzneimittel GmbH & Co.KG Pharmazeutisches Präparat
US20100269989A1 (en) 2009-04-28 2010-10-28 Enzymatic Deinking Technologies, L.L.C. Use of 1,3-selective lipases for pitch control in pulp and paper processes
BRPI1009920A2 (pt) 2009-05-01 2016-03-15 Micropharma Ltd composições bacterianas para profilaxina e tratamento de doença degenerativa.
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides

Also Published As

Publication number Publication date
EP2758070B1 (en) 2019-11-06
US8268305B1 (en) 2012-09-18
CA2849250A1 (en) 2013-03-28
AU2012312661A1 (en) 2014-03-20
US9555083B2 (en) 2017-01-31
US20140294802A1 (en) 2014-10-02
BR112014007042A2 (pt) 2017-04-11
WO2013043587A1 (en) 2013-03-28
JP6170051B2 (ja) 2017-07-26
EP2758070A4 (en) 2015-03-25
AU2012312661B2 (en) 2017-02-09
EP2758070A1 (en) 2014-07-30
MX368742B (es) 2019-10-14
MX2014003478A (es) 2015-04-16
CA2849250C (en) 2021-03-23
JP2014526553A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
BR112017024928A2 (pt) Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112013000446A2 (pt) composição nutricional para a estimulação de síntese de proteína muscular
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112015007782A2 (pt) laquinimod para reduzir danos talâmicos na esclerose múltipla
BR112014013876A2 (pt) vacina à base de toxina de clostridium difficile
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
BR112014027995A2 (pt) uso de seaprose para remover biopelícula bacteriana
BR112015004515A2 (pt) composição imunogênica
BR112012018703A2 (pt) compostos e seus efeitos sobre o comportamento alimentar
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: BIO-CAT, INC. (US) , KENNETH GREGORY MOORE (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: BIO-CAT, INC. (US) , KENNETH GREGORY MOORE (US)

B25A Requested transfer of rights approved

Owner name: BIO-CAT, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements